NCT00219609已完成2 期
A Phase 2 Multi-Center, Open Label Long-Term Extension Trial To Assess The Safety Of Oral Uk-390,957 Administered As Required In Adult Men With Premature Ejaculation
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 1,058
- 试验地点
- 82
- 主要终点
- Assessment of safety
研究概览
简要总结
To determine whether UK-390,957 is a safe treatment for premature ejaculation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subjects will have completed one of the phase 2 trials (A3871022/ A3871027/ A3871029) and will have met the diagnostic criteria for premature ejaculation as defined by DSM-IV
排除标准
- •No drug related serious adverse events
结局指标
主要结局
Assessment of safety
次要结局
未报告次要终点
研究者
研究点 (82)
Loading locations...
相似试验
已完成
2 期
Assessment of Efficacy and Safety of UK-390,957 in Men With Premature EjaculationEjaculationNCT00143117Pfizer460
已完成
2 期
A Study On Concentrations Of 16448 In Blood And The Safety Of This Compound In Healthy Males With Premature EjaculationPremature EjaculationNCT00537459GlaxoSmithKline18
Unknown
3 期
Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile DysfunctionErectile DysfunctionPremature EjaculationNCT04361305Yan-Ping Huang150
已完成
2 期
Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature EjaculationEjaculationNCT00219583Pfizer460
终止
2 期
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationEsophageal CancerNCT06682806Prelude Therapeutics6